Long-term Follow-up from Phase II JULIET Study Suggests Durable Improvement in HRQoL

These data, in combination with durable complete responses and overall survival data, suggested that tisagenlecleucel improved health-related quality of life in adult patients with relapsed or refractory diffuse large B-cell lymphoma who respond to treatment.

Source: CancerNetwork - February 24, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news